In this new role, Mr Baker will be responsible for overseeing the company's commercial development, strategic planning, business development, investor relations, corporate communications, finance and accounting, operations and legal affairs.
With Mr Baker's appointment, Progenics's newly expanded board now has nine members. Prior to his promotion, Mr Baker was executive vice president of corporate. Mr Baker joined the company in 2005 as senior vice president and general counsel.
Dr Maddon said: "Over the last four years, Mark has been the architect of our business development efforts, having negotiated our agreements with Wyeth and Ono Pharmaceuticals. His appointment as president and director not only recognizes the significant contributions he has made to Progenics, but calls upon him to provide direction and leadership in developing the company's business and commercial capabilities."
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index